SYNDAX PHARMACEUTICALS INC's ticker is SNDX and the CUSIP is 87164F105. A total of 100 filers reported holding SYNDAX PHARMACEUTICALS INC in Q2 2020. The put-call ratio across all filers is 0.28 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2020 | $0 | -100.0% | 59 | -93.9% | 0.00% | -100.0% |
| Q1 2020 | $11,000 | +22.2% | 960 | -16.0% | 0.00% | 0.0% |
| Q4 2019 | $9,000 | +80.0% | 1,143 | +83.5% | 0.00% | – |
| Q3 2019 | $5,000 | 0.0% | 623 | +25.4% | 0.00% | – |
| Q2 2019 | $5,000 | +400.0% | 497 | +98.0% | 0.00% | – |
| Q1 2019 | $1,000 | -50.0% | 251 | +24.3% | 0.00% | – |
| Q3 2018 | $2,000 | 0.0% | 202 | +39.3% | 0.00% | – |
| Q1 2018 | $2,000 | -33.3% | 145 | -33.8% | 0.00% | – |
| Q2 2017 | $3,000 | 0.0% | 219 | -1.4% | 0.00% | – |
| Q1 2017 | $3,000 | +50.0% | 222 | +2.8% | 0.00% | – |
| Q4 2016 | $2,000 | – | 216 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Kynam Capital Management, LP | 3,600,000 | $52,272,000 | 8.55% |
| Foresite Capital Management IV, LLC | 875,000 | $12,705,000 | 7.06% |
| Aisling Capital Management LP | 1,025,000 | $14,883,000 | 6.13% |
| Saturn V Capital Management LP | 807,969 | $11,731,710 | 4.91% |
| Eversept Partners, LP | 2,596,245 | $37,697,477 | 3.19% |
| ACUTA CAPITAL PARTNERS, LLC | 297,035 | $4,312,948 | 2.89% |
| Paradigm Biocapital Advisors LP | 2,390,077 | $34,703,918 | 2.36% |
| DAFNA Capital Management LLC | 458,373 | $6,655,576 | 2.07% |
| SPHERA FUNDS MANAGEMENT LTD. | 773,061 | $11,224,846 | 2.04% |
| PFM Health Sciences, LP | 2,715,235 | $39,425,212 | 1.86% |